University of Tsukuba
11
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
Role: collaborator
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Role: collaborator
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Role: collaborator
COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the Psychological Burden of Coronavirus
Role: collaborator
Brugada Ablation of VF Substrate Ongoing MultiCenter Registry
Role: collaborator
Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.
Role: collaborator
New Technology for Individualised, Intensive Training of Gait After Stroke Study I
Role: collaborator
Prospective Identification of Long QT Syndrome in Fetal Life
Role: collaborator
New Technology for Individualised, Intensive Training of Gait After Stroke- Study II
Role: collaborator
A Comparison Between the Exoskeleton Hybrid Assistive Limb and Conventional Gait Training Early After Stroke
Role: collaborator
Acupuncture for Whiplash Associated Disorder
Role: collaborator
All 11 trials loaded